JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Two significant complications following percutaneous needle fasciotomy in a patient on anticoagulants.

Percutaneous needle fasciotomy treatment of Dupuytren's disease has been used on the continent for over two decades but has only recently gained popularity in the UK. The National Institute for Clinical Excellence published guidance in February 2004 stating that the procedure is safe and effective. We report a case of two complications in the same patient following the use of the technique, on only one occasion, in a patient who was anticoagulated. We believe that it is the first time that a false aneurysm has been reported following the procedure and that this was probably related to the inhibited coagulation cascade. The patient also sustained an injury to flexor digitorum profundus but had an intact superficialis tendon and we find it difficult to explain this occurrence. We report the above complication as we feel this technique may be chosen specifically in patients with co-existing medical problems such as anticoagulation.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app